Literature DB >> 26518190

Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study.

Yoshitaka Hashimoto1, Muhei Tanaka1, Hiroshi Okada2, Kazuteru Mistuhashi1, Toshihiro Kimura1, Noriyuki Kitagawa1, Takuya Fukuda1, Saori Majima1, Yukiko Fukuda1, Yoshimitsu Tanaka1, Shunji Yamada3, Takafumi Senmaru1, Masahide Hamaguchi1, Mai Asano1, Masahiro Yamazaki1, Yohei Oda1, Goji Hasegawa2, Naoto Nakamura1, Michiaki Fukui4.   

Abstract

Taking metformin with a meal has been shown to decrease bioavailability of metformin. We hypothesized that taking metformin 30 min before a meal improves glucose metabolism. As an animal model, 18 Zucker-rats were divided into three groups as follows: no medication (Control), metformin (600 mg/kg) with meal (Met), and metformin 10 min before meal (pre-Met). In addition, five diabetic patients were recruited and randomized to take metformin (1000 mg) either 30 min before a meal (pre-Met protocol) or with a meal (Met protocol). In the animal model, the peak glucose level of pre-Met (7.8 ± 1.5 mmol/L) was lower than that of Control (12.6 ± 2.5 mmol/L, P = 0.010) or Met (14.1 ± 2.9 mmol/L, P = 0.020). Although there was no statistical difference among the three groups, total GLP-1 level at t = 0 min of pre-Met (7.4 ± 2.7 pmol/L) tended to be higher than that of Control (3.7 ± 2.0 pmol/L, P = 0.030) or Met (3.9 ± 1.2 pmol/L, P = 0.020). In diabetic patients, the peak glucose level of pre-Met protocol (7.0 ± 0.4 mmol/L) was lower than that of Met protocol (8.5 ± 0.9 mmol/L, P = 0.021). Total GLP-1 level at t = 30 min of pre-Met protocol (11.0 ± 6.1 pmol/L) was higher than that of Met protocol (6.7 ± 3.9 pmol/L, P = 0.033). Taking metformin 30 min before a meal ameliorated postprandial hyperglycemia. This promises to be a novel approach for postprandial hyperglycemia.

Entities:  

Keywords:  Biguanides; Gastric emptying; Glucagon-like peptide-1 (GLP-1); Incretin; Metformin; Postprandial hyperglycemia; Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26518190     DOI: 10.1007/s12020-015-0786-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  20 in total

1.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin.

Authors:  T Nakagami
Journal:  Diabetologia       Date:  2004-02-18       Impact factor: 10.122

2.  Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

Authors:  Brian D Green; Nigel Irwin; Nicola A Duffy; Victor A Gault; Finbarr P M O'harte; Peter R Flatt
Journal:  Eur J Pharmacol       Date:  2006-07-27       Impact factor: 4.432

3.  The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Authors:  Bogdan Balas; Muhammad R Baig; Catherine Watson; Beth E Dunning; Monica Ligueros-Saylan; Yibin Wang; Yan-Ling He; Celia Darland; Jens J Holst; Carolyn F Deacon; Kenneth Cusi; Andrea Mari; James E Foley; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2007-01-23       Impact factor: 5.958

Review 4.  GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.

Authors:  Jennifer M Trujillo; Wesley Nuffer
Journal:  Pharmacotherapy       Date:  2014-11       Impact factor: 4.705

5.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

Authors:  M Tominaga; H Eguchi; H Manaka; K Igarashi; T Kato; A Sekikawa
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

6.  Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

Authors:  Juris J Meier; Guido Kemmeries; Jens J Holst; Michael A Nauck
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

7.  Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.

Authors:  E Mannucci; A Ognibene; F Cremasco; G Bardini; A Mencucci; E Pierazzuoli; S Ciani; G Messeri; C M Rotella
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

8.  Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans.

Authors:  J Borovicka; C Kreiss; K Asal; B Remy; C Mettraux; A Wells; N W Read; J B Jansen; M D'Amato; A B Delaloye; M Fried; W Schwizer
Journal:  Am J Physiol       Date:  1996-09

9.  Efficacy of lactulose plus 13C-acetate breath test in the diagnosis of gastrointestinal motility disorders.

Authors:  Yoshihisa Urita; Kazuo Hike; Naotaka Torii; Yoshinori Kikuchi; Masahiko Sasajima; Kazumasa Miki
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

Review 10.  Erythromycin: a motilin agonist and gastrointestinal prokinetic agent.

Authors:  F H Weber; R D Richards; R W McCallum
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

View more
  5 in total

1.  Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study.

Authors:  Takuro Okamura; Yoshitaka Hashimoto; Masahide Hamaguchi; Akihiro Obora; Takao Kojima; Michiaki Fukui
Journal:  BMC Gastroenterol       Date:  2021-05-17       Impact factor: 3.067

2.  Acute Effect of Metformin on Postprandial Hypertriglyceridemia through Delayed Gastric Emptying.

Authors:  Daisuke Sato; Katsutaro Morino; Fumiyuki Nakagawa; Koichiro Murata; Osamu Sekine; Fumiaki Beppu; Naohiro Gotoh; Satoshi Ugi; Hiroshi Maegawa
Journal:  Int J Mol Sci       Date:  2017-06-16       Impact factor: 5.923

3.  Transcriptomic landscape profiling of metformin-treated healthy mice: Implication for potential hypertension risk when prophylactically used.

Authors:  Yuhong Meng; Rui Xiang; Han Yan; Yiran Zhou; Yuntao Hu; Jichun Yang; Yuan Zhou; Qinghua Cui
Journal:  J Cell Mol Med       Date:  2020-06-11       Impact factor: 5.310

Review 4.  Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.

Authors:  Mariël F van Stee; Albert A de Graaf; Albert K Groen
Journal:  Cardiovasc Diabetol       Date:  2018-06-30       Impact factor: 9.951

5.  Efficacy of metformin on postprandial plasma triglyceride concentration by administration timing in patients with type 2 diabetes mellitus: A randomized cross-over pilot study.

Authors:  Daisuke Sato; Katsutaro Morino; Seiichiro Ogaku; Akiko Tsuji; Kimihiro Nishimura; Osamu Sekine; Satoshi Ugi; Hiroshi Maegawa
Journal:  J Diabetes Investig       Date:  2019-02-22       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.